Abgentil Biomedical was founded with the mission of transforming innovative technology into real-world solutions for cancer and rare disease treatment. Our commitment to continuous research and development is driven by a leading scientific team operating in a state-of-the-art laboratory.
At Abgentil Biomedical, we are proud to provide a range of advanced treatments and services, including:
- CAR-T Therapy: Engineered T cells designed to target and eliminate cancer cells.
- Tumor-Infiltrating Lymphocytes (TIL): Harnessing the body’s own immune cells to combat tumors.
- TCR Therapy: T cell receptors engineered to specifically recognize tumor antigens.
- BiTE Antibodies: Bispecific antibodies that engage T cells to target and destroy cancer cells.
- mRNA Lipid Nanoparticles (LNP): Innovative delivery systems for mRNA-based therapies.
- DC-CIK Therapy: Combining dendritic cells and cytokine-induced killer cells for enhanced immune response.
- Medical Tourism: Offering access to cutting-edge treatments for international patients.
Commitment to Innovation
With a focus on pioneering new ideas through research, Abgentil Biomedical is dedicated to improving patient outcomes and advancing the field of cancer and rare disease therapies. Our ongoing R&D efforts aim to bring forth transformative solutions that can make a significant impact on patients’ lives.
